SAN

83.44

+0.54%↑

MRK1

109.55

-2.62%↓

SHL.DE

45.99

-0.73%↓

ARGX

486.4

+1.95%↑

FRE

41.9

+0.07%↑

SAN

83.44

+0.54%↑

MRK1

109.55

-2.62%↓

SHL.DE

45.99

-0.73%↓

ARGX

486.4

+1.95%↑

FRE

41.9

+0.07%↑

SAN

83.44

+0.54%↑

MRK1

109.55

-2.62%↓

SHL.DE

45.99

-0.73%↓

ARGX

486.4

+1.95%↑

FRE

41.9

+0.07%↑

SAN

83.44

+0.54%↑

MRK1

109.55

-2.62%↓

SHL.DE

45.99

-0.73%↓

ARGX

486.4

+1.95%↑

FRE

41.9

+0.07%↑

SAN

83.44

+0.54%↑

MRK1

109.55

-2.62%↓

SHL.DE

45.99

-0.73%↓

ARGX

486.4

+1.95%↑

FRE

41.9

+0.07%↑

Search

Orion Oyj (Class B)

Cerrado

66.25 -0.45

Resumen

Variación precio

24h

Actual

Mínimo

65.9

Máximo

66.75

Métricas clave

By Trading Economics

Ingresos

-12M

61M

Ventas

-80M

355M

P/B

Media del Sector

25.565

39.564

BPA

0.44

Rentabilidad por dividendo

2.57

Margen de beneficio

17.287

Empleados

3,943

EBITDA

202M

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.57%

2.40%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

3.4B

8.9B

Apertura anterior

66.7

Cierre anterior

66.25

Orion Oyj (Class B) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 jul 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Principales Movimientos del Mercado

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Ganancias

BASF Cuts Outlook on Global Economy Uncertainty

13 jul 2025, 23:54 UTC

Charlas de Mercado

Oil Edges Higher Amid Supply Disruption Worries -- Market Talk

13 jul 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

13 jul 2025, 23:49 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 jul 2025, 23:40 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

13 jul 2025, 23:40 UTC

Charlas de Mercado

Gold Advances Amid Rising Trade Tensions -- Market Talk

13 jul 2025, 23:39 UTC

Charlas de Mercado

China's Growth Momentum Likely Slowed in 2Q -- Market Talk

13 jul 2025, 23:16 UTC

Ganancias

China Shenhua Energy 1H 2024 Net Was CNY32.8B>1088.HK

13 jul 2025, 23:16 UTC

Ganancias

China Shenhua Energy: Drop in Coal Prices Weighed on Results >1088.HK

13 jul 2025, 23:16 UTC

Ganancias

China Shenhua Energy Sees 1H Net CNY25.6B-Net CNY27.6B >1088.HK

13 jul 2025, 23:13 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 jul 2025, 23:13 UTC

Charlas de Mercado

Ryman Healthcare Could Be Turning a Corner -- Market Talk

13 jul 2025, 11:00 UTC

Adquisiciones, fusiones, absorciones

The Private-Equity Maneuver Allowing More Investors to Cash Out -- WSJ

12 jul 2025, 02:24 UTC

Adquisiciones, fusiones, absorciones

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11 jul 2025, 21:45 UTC

Charlas de Mercado

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Adquisiciones, fusiones, absorciones

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Charlas de Mercado

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Charlas de Mercado

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Charlas de Mercado

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Charlas de Mercado

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Charlas de Mercado

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Ganancias

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Charlas de Mercado

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Ganancias

BASF Will Publish Half-Year Results on July 30

Comparación entre iguales

Cambio de precio

Orion Oyj (Class B) Esperado

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.